Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- LDP Legislators Push for “No Off-Year Price Revision”: Health Committee
November 16, 2022
- LDP Lawmakers Throw Support Behind Pharma on Off-Year Plan
November 15, 2022
- Japan’s 4th Avastin Biosimilar, Kit Products Get Listing; No Follow-On for New API in FY2022
November 15, 2022
- LEO Pharma’s Atopic Dermatitis Med Tralokinumab Up for MHLW Panel Review on November 28
November 15, 2022
- Shionogi’s COVID Pill Up for 3rd Round of Discussion for Emergency Approval on Nov. 22
November 15, 2022
- Teikoku’s Donepezil Tape, AbbVie’s Parkinson’s Med Up for PAFSC Review on Nov. 25
November 14, 2022
- 2 Women Die after BA.5 COVID Booster Shots: MHLW
November 14, 2022
- Kokando Told to Suspend Business for Up to 36 Days over Decades-Long Violations
November 14, 2022
- Online Submissions for Generic Approval to Start from January
November 14, 2022
- Pro-Industry Lawmakers, Govt Remain Widely Divided over Off-Year Plan
November 11, 2022
- MHLW Reserves Extra Budget to Build Gene Therapy Support Consortium
November 11, 2022
- Drug Price Negotiations by Consultants Might Violate Distribution Guidelines: Official
November 11, 2022
- Zero Coefficient Rule Hits All 10 Premium-Granted Drugs Priced by Cost Formula in FY2022
November 11, 2022
- Japan to Roll Out Moderna’s BA.4/5 Booster from Nov. 28
November 11, 2022
- Expert Panel Discussion Summary Reported to Chuikyo; Payer Rep Sees No Need for Inflation Response in Off Year
November 10, 2022
- Polivy Likely to Escape CEA-Based Price Tweaks
November 10, 2022
- MHLW Earmarks 55 Billion Yen for Domestic Antibiotic API Production: Extra Budget
November 10, 2022
- Extra Budget to Cover Enough COVID Vaccine Purchases until Next Winter
November 10, 2022
- METI Looks to Bolster Pharma Startup Ecosystem with 6-Fold Hike in Extra Budget
November 10, 2022
- Skyrizi Auto-Doser Peak Sales Put at 30-Plus Billion Yen, Mounjaro Not on Roster: November Listing
November 10, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…